Systemic Lupus Erythematosus (SLE; «lupus») begins several years before the actual time of diagnosis, when a person has no or very mild symptoms but her/his immune cells start malfunctioning and produces antinuclear («ANAs») and other auto-antibodies (so called «preclinical lupus»). This gives an opportunity for planning preventive strategies which could potentially restore immune system function and delay (or even, prevent) lupus.
Project LeadG Bertsias
Year 1-2: Recruitment (inception cohort), biobanking
Year 1-5: Monitoring (inception cohort)
Year 3-5: RNA extraction, RNA-seq, bioinformatics
Year 3-5: Analysis of cohort data, prediction score
The Arthritis Foundation of Crete and Lu- pus Europe participate in the consortium and have been involved in the discussions and the design of the study. Their representatives will participate in all consortium meetings where the study details will be ﬁnalized and the results will be presented and discussed.
In all phases, the patients‘ views will be incorporated as much as possible. Besides helping with patient recruitment and retention strategies (possible risk of the project), the Foundation will assist in interpretation and dissemination of the results.